These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37203069)

  • 1. Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes - A multicentric study.
    Chakraborty D; Mondal S; Sengupta S; Abbas Z; Chandra K; Boral S; Maiti A; Roy S; Mukherjee A; Das A; Chakraborty S; Nag P
    Indian J Ophthalmol; 2023 May; 71(5):1979-1985. PubMed ID: 37203069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER.
    Singer M; Albini TA; Seres A; Baumal CR; Parikh S; Gale R; Kaiser PK; Lobach I; Feltgen N; Joshi MR; Ziemssen F; Bodaghi B
    Ophthalmol Retina; 2022 Feb; 6(2):97-108. PubMed ID: 33971353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
    Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
    Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and Management of Intraocular Inflammation after Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration.
    Bodaghi B; Souied EH; Tadayoni R; Weber M; Ponthieux A; Kodjikian L
    Ophthalmol Retina; 2023 Oct; 7(10):879-891. PubMed ID: 37343623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.
    Khanani AM; Zarbin MA; Barakat MR; Albini TA; Kaiser PK; B G; Agashivala N; Yu JS; Wykoff CC; MacCumber MW
    JAMA Ophthalmol; 2022 Jan; 140(1):20-28. PubMed ID: 34817566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: A Multicenter Age-Related Macular Degeneration Study.
    Inoda S; Takahashi H; Maruyama-Inoue M; Ikeda S; Sekiryu T; Itagaki K; Matsumoto H; Mukai R; Nagai Y; Ohnaka M; Kusuhara S; Miki A; Okada AA; Nakayama M; Nishiguchi KM; Takeuchi J; Mori R; Tanaka K; Honda S; Kohno T; Koizumi H; Miyara Y; Inoue Y; Takana H; Iida T; Maruko I; Hayashi A; Ueda-Consolvo T; Yanagi Y
    Retina; 2024 Apr; 44(4):714-722. PubMed ID: 38016089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INTRAOCULAR INFLAMMATION INCIDENCE AFTER INTRAVITREAL BROLUCIZUMAB INJECTION FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Pakravan P; Patel V; Lai J; Shaheen A; Kalahasty K; Reyes-Capo DP; Chau V; Rosenfeld PJ; Haddock LJ; Schwartz SG; Smiddy WE; Kovach JL; Sridhar J; Flynn HW; Albini TA; Yannuzzi NA
    Retina; 2023 Oct; 43(10):1717-1722. PubMed ID: 37320859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study.
    Kim DJ; Jin KW; Han JM; Lee SH; Park YS; Lee JY; Lee EK; Lee JS; Kim ST; Shin MH; Lee CS; Jung HH; Jang JY; Kim M; Kim YH; Kim JH; Park KH; Park SJ; Joo K; Ji YS; Sagong M; Woo SJ
    Ophthalmologica; 2023; 246(3-4):192-202. PubMed ID: 36720210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual outcomes of intraocular inflammation after brolucizumab injection in Japanese patients with neovascular age-related macular degeneration.
    Hirono K; Maruyama-Inoue M; Yanagi Y; Kadonosono K
    PLoS One; 2024; 19(4):e0302295. PubMed ID: 38635732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab.
    Hoshi K; Kunikata H; Aizawa N; Yasuda M; Okabe T; Takizawa H; Abe T; Nakazawa T
    Int Ophthalmol; 2023 Dec; 43(12):4701-4709. PubMed ID: 38044420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sub-Tenon's capsule triamcinolone acetonide injection to prevent brolucizumab-associated intraocular inflammation.
    Hikichi T
    Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2529-2535. PubMed ID: 35235038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age-related macular degeneration.
    Sotani R; Matsumiya W; Kim KW; Miki A; Yasuda E; Maeda Y; Hara R; Kusuhara S; Nakamura M
    Graefes Arch Clin Exp Ophthalmol; 2023 Aug; 261(8):2359-2366. PubMed ID: 36971800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab.
    Zubricky R; McCoy J; Donkor R; Miller DG; Sonbolian N; Heaney A; Bilano V; Karcher H; Coney JM
    Ophthalmol Ther; 2023 Oct; 12(5):2397-2408. PubMed ID: 37310683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.
    Baumal CR; Spaide RF; Vajzovic L; Freund KB; Walter SD; John V; Rich R; Chaudhry N; Lakhanpal RR; Oellers PR; Leveque TK; Rutledge BK; Chittum M; Bacci T; Enriquez AB; Sund NJ; Subong ENP; Albini TA
    Ophthalmology; 2020 Oct; 127(10):1345-1359. PubMed ID: 32344075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review on the Safety and Efficacy of Brolucizumab for Neovascular Age-Related Macular Degeneration From Major Studies and Real-World Data.
    Radke NV; Mohamed S; Brown RB; Ibrahim I; Chhablani J; Amin SV; Tsang CW; Brelen ME; Raichand NS; Fang D; Zhang S; Dai H; Chen GLJ; Cheung CMG; Hariprasad SM; Das T; Lam DSC
    Asia Pac J Ophthalmol (Phila); 2023 Mar-Apr 01; 12(2):168-183. PubMed ID: 36971706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
    Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
    Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment.
    Ueji N; Mase Y; Kubo A; Matsubara H; Chujo S; Matsui Y; Kondo M
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893574
    [No Abstract]   [Full Text] [Related]  

  • 18. A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment.
    Holz FG; Iida T; Maruko I; Sadda SR
    Retina; 2022 Sep; 42(9):1629-1637. PubMed ID: 35994582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EXUDATIVE RETINAL DETACHMENT AFTER INTRAVITREAL BROLUCIZUMAB INJECTION.
    Betsch DM; Sarraf D; Francisconi CLM
    Retin Cases Brief Rep; 2023 Jul; 17(4):463-465. PubMed ID: 36893333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RISK OF INTRAOCULAR INFLAMMATION AFTER INJECTION OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS: A Meta-analysis.
    Patil NS; Dhoot AS; Popovic MM; Kertes PJ; Muni RH
    Retina; 2022 Nov; 42(11):2134-2142. PubMed ID: 36269802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.